Dr. Adi Mor, CEO and CSO, co-founded Chemomab in 2011. She has extensive knowledge and experience in immunology focusing on autoimmune and inflammatory diseases and broad experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and fibrotic diseases. Dr. Mor earned her PhD in immunology from Tel. Aviv University in the Department of Neurobiochemistry and is the lead author of numerous scientific journal publications in immunology and inflammatory disorders.
